Overall, Mitralign offers a promising solution for interventional cardiologists and their patients, addressing a critical unmet need in the treatment of mitral and tricuspid valve regurgitation. With their innovative technology and compelling market potential, the company presents an intriguing opportunity for venture capitalists seeking to invest in the health care industry.
General Information
BounceWatch is an independent company data service, not affiliated with Mitralign Inc.. To contact Mitralign Inc., visit mitralign.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Mitralign Inc. compare?
A PDF of Mitralign Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Mitralign Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Health Care
About Mitralign Inc.
Business keywords: Medical Innovation, Cardiac Technology, Mitral Valve Repair, Tricuspid Valve Repair, Percutaneous Treatment, Interventional Cardiology, Venture-backed, Catheter-based Technology, Functional Mitral Regurgitation, Transcatheter Annuloplasty, Investigational Device, Top Tier Venture Capitalists, Cardiovascular Device, Startup
Funding Rounds & Investors (12)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $9.77M | - |
|
02 Feb 2018 |
| Series E | $39.80M | - |
|
17 May 2016 |
| Series E | $23.00M | 1 | 01 Jan 2015 | |
| Venture Round | $8.00M | 1 | 20 Jun 2014 | |
| Venture Round | $1.90M | 1 | 26 Oct 2012 | |
| Debt Financing | $7.00M | - |
|
11 Sep 2012 |
| Series D | $35.00M | 6 | 16 May 2012 | |
| Series C | $24.00M | 8 | 31 Dec 2007 | |
| Series B | $13.00M | 4 | 30 Jun 2006 | |
| Series B | $3.30M | 1 | 20 Apr 2006 |
Mitralign Inc. Alternatives & Competitors
View All AlternativesAdvanced transcatheter therapy for resilient heart health and optimal blood flow
Designing the future of cardiac valve repair through innovative non-surgical solutions.
Pioneering minimally invasive mitral valve repair solutions for effective heart disease treatment
FAQ About Mitralign Inc.
Source: BounceWatch company record for Mitralign Inc., https://bouncewatch.com/company/mitralign, updated 1 December 2024. When citing, please name BounceWatch and link this page.